Author | Le Gars, Mathieu | |
Author | Sadoff, Jerald | |
Author | Struyf, Frank | |
Author | Heerwegh, Dirk | |
Author | Truyers, Carla | |
Author | Hendriks, Jenny | |
Author | Gray, Glenda | |
Author | Grinsztejn, Beatriz | |
Author | Goepfert, Paul A. | |
Author | Schuitemaker, Hanneke | |
Author | Douoguih, Macaya | |
Access date | 2022-12-11T12:24:40Z | |
Available date | 2022-12-11T12:24:40Z | |
Document date | 2022 | |
Citation | LE GARS, Mathieu et al. Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. The Journal of infectious diseases, v. 226, n. 6, p. 979-982, 2022. | en_US |
ISSN | 0022-1899 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/55904 | |
Language | eng | en_US |
Publisher | Oxford | en_US |
Rights | restricted access | en_US |
Title | Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine | en_US |
Type | Article | en_US |
DOI | 10.1093/infdis/jiac142 | |
Abstract | This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein-binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses. | en_US |
Affilliation | Janssen Vaccines and Prevention. Leiden, the Netherlands. | en_US |
Affilliation | Janssen Vaccines and Prevention. Leiden, the Netherlands. | en_US |
Affilliation | Janssen Research and Development. Beerse, Belgium. | en_US |
Affilliation | Janssen Research and Development. Beerse, Belgium. | en_US |
Affilliation | Janssen Research and Development. Beerse, Belgium. | en_US |
Affilliation | Janssen Vaccines and Prevention. Leiden, the Netherlands. | en_US |
Affilliation | South African Research Council. Cape Town, South Africa. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | University of Alabama. Department of Medicine. Birmingham, Alabama, USA. | en_US |
Affilliation | Janssen Vaccines and Prevention. Leiden, the Netherlands. | en_US |
Affilliation | Janssen Vaccines and Prevention. Leiden, the Netherlands. | en_US |
Subject | Ad26.COV2.S | en_US |
Subject | COVID-19 | en_US |
Subject | SARS-CoV-2 | en_US |
Subject | Preexisting immunity | en_US |
Subject | Vaccine | en_US |